An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

ABSTRACT:

Background

Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed.

Methods

We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes w

SUBMITTER: Herold KC 

PROVIDER: S-EPMC6776880 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature